Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007749
Filing Date
2025-05-14
Accepted
2025-05-14 16:10:27
Documents
66
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mtva-20250331x10q.htm   iXBRL 10-Q 986627
2 EX-31.1 mtva-20250331xex31d1.htm EX-31.1 38103
3 EX-31.2 mtva-20250331xex31d2.htm EX-31.2 38313
4 EX-32.1 mtva-20250331xex32d1.htm EX-32.1 8224
5 EX-32.2 mtva-20250331xex32d2.htm EX-32.2 8432
6 GRAPHIC mtva-20250331x10q001.jpg GRAPHIC 9472
  Complete submission text file 0001558370-25-007749.txt   5189278

Data Files

Seq Description Document Type Size
7 EX-101.SCH mtva-20250331.xsd EX-101.SCH 39095
8 EX-101.CAL mtva-20250331_cal.xml EX-101.CAL 38533
9 EX-101.DEF mtva-20250331_def.xml EX-101.DEF 114377
10 EX-101.LAB mtva-20250331_lab.xml EX-101.LAB 321930
11 EX-101.PRE mtva-20250331_pre.xml EX-101.PRE 235303
69 EXTRACTED XBRL INSTANCE DOCUMENT mtva-20250331x10q_htm.xml XML 904710
Mailing Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 545 CONCORD AVENUE SUITE 210 CAMBRIDGE MA 02138 (857) 702-9600
MetaVia Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 25945554
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)